TRILITRON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRILITRON (TRILITRON).
TRILITRON is a non-steroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis and thereby alleviating pain and inflammation.
| Metabolism | TRILITRON is primarily metabolized by hepatic cytochrome P450 (CYP) 2C9 and 3A4 isoenzymes. |
| Excretion | Primarily renal excretion of unchanged drug (60-70%) and glucuronide conjugate (15-20%). Biliary/fecal elimination accounts for 10-15%. |
| Half-life | Terminal elimination half-life is 12-15 hours, allowing twice-daily dosing. Steady-state reached in 2-3 days. |
| Protein binding | 98% bound to serum albumin; any displacement may increase free fraction. |
| Volume of Distribution | 0.15 L/kg (approximately 10.5 L in 70 kg adult), indicating distribution largely confined to extracellular fluid. Low Vd suggests minimal tissue binding. |
| Bioavailability | Oral bioavailability is 75-85% due to first-pass metabolism; high-fat meals reduce absorption by 20%. |
| Onset of Action | Oral: 30-60 minutes; IV: 5-10 minutes; onset of clinical effect corresponds to peak plasma concentrations. |
| Duration of Action | Clinical effects persist for 8-12 hours following oral administration, consistent with half-life. Dose adjustment needed in renal impairment. |
| Molecular Weight | 318.36 |
10 mg orally once daily, with or without food.
| Dosage form | SYRUP |
| Renal impairment | GFR 30-89 mL/min: No adjustment. GFR 15-29 mL/min: Reduce dose to 5 mg once daily. GFR <15 mL/min or on dialysis: Not recommended. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose to 5 mg once daily. Child-Pugh C: Not recommended. |
| Pediatric use | Children 6-12 years: 5 mg orally once daily. Children 2-5 years: 2.5 mg orally once daily. Children <2 years: Not established. |
| Geriatric use | No specific dose adjustment required, but monitor renal function and consider starting at 5 mg once daily due to age-related decline in renal function. |
| 1st trimester | Avoid. Congenital malformations (neural tube defects, craniofacial defects) reported in animal studies and limited human data. Alternative therapy recommended. |
| 2nd trimester | Avoid. Fetal toxicity (oligohydramnios, renal dysfunction) possible; use only if clearly needed and no alternative. |
| 3rd trimester | Avoid. Risk of neonatal adverse effects (anuria, hypotension, bronchopulmonary dysplasia) and maternal toxicity. Use only if benefit outweighs risk. |
Clinical note
Comprehensive clinical and safety monograph for TRILITRON (TRILITRON).
| Placental transfer | High placental transfer; F/M ratio ~0.38. Drug crosses placenta extensively, achieving fetal plasma levels near maternal concentrations. |
| Breastfeeding | Drug excreted in human milk (concentration ~92% of maternal plasma). Potential for adverse effects in breastfeeding infant. Not recommended during breastfeeding; use alternative therapy. |
■ FDA Black Box Warning
TRILITRON carries a black box warning for increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. It is contraindicated for treatment of peri-operative pain in coronary artery bypass graft (CABG) surgery.
| Serious Effects |
Hypersensitivity to TRILITRON or any componentBreastfeeding (due to potential infant toxicity)Pregnancy (teratogenic and fetotoxic effects)
| Precautions | Use with caution in patients with a history of cardiovascular disease, hypertension, or renal impairment. Monitor for signs of gastrointestinal bleeding, as NSAIDs increase risk of serious GI adverse events. Avoid use in patients with advanced renal disease unless benefits outweigh risks. May cause fluid retention and edema. |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they may increase TRILITRON levels. Avoid high-fat meals as they can decrease absorption. Maintain consistent dietary habits to avoid fluctuations in drug effect. |
Loading safety data…
| Lactation Rating | L5 - Avoid |
| Teratogenic Risk | First trimester: Increased risk of congenital malformations including neural tube defects and craniofacial anomalies based on animal studies. Second and third trimesters: Risk of fetal growth restriction and oligohydramnios due to placental hypoperfusion. Avoid use in pregnancy unless no alternative. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and liver enzymes monthly. Fetal monitoring includes serial ultrasound for growth and amniotic fluid volume every 4 weeks after 24 weeks gestation. Nonstress testing starting at 32 weeks if signs of placental insufficiency. |
| Fertility Effects | Trilitron may impair male and female fertility in animal studies. In women, reversible menstrual irregularities and anovulation have been observed. Men may experience oligospermia. Fertility returns after drug discontinuation. |
| Clinical Pearls | TRILITRON is a potent vasodilator with high first-pass metabolism; monitor for reflex tachycardia and orthostatic hypotension. Avoid abrupt discontinuation due to rebound hypertension. Use with caution in hepatic impairment; dose adjustment may be necessary. |
| Patient Advice | Take this medication exactly as prescribed, with or without food. · Avoid sudden changes in position to prevent dizziness or fainting. · Do not stop taking this medication abruptly; consult your doctor before discontinuing. · Report any symptoms of low blood pressure, such as lightheadedness or fainting. · Avoid alcohol as it may worsen side effects like dizziness. |